Chika Yamagishi

机构：ABB (Japan), AbbVie (Japan) · ORCID：0000-0001-5501-6390

发表论文 8 篇 · 总被引 69 次 · h-index 4

代表论文

Multi-omics analysis defines highly refractory RAS burdened immature subgroup of infant acute lymphoblastic leukemia (2022 · Nature Communications · 被引 36)
Hematopoietic Cell Transplantation with Reduced Intensity Conditioning Using Fludarabine/Busulfan or Fludarabine/Melphalan for Primary Immunodeficiency Diseases (2021 · Journal of Clinical Immunology · 被引 18)
Interim results from a postmarketing surveillance study of patients with FLT3-mutated relapsed/refractory AML treated with the FLT3 inhibitor gilteritinib in Japan (2022 · Japanese Journal of Clinical Oncology · 被引 11)
Myeloid/natural killer (NK) cell precursor acute leukemia as a distinct leukemia type (2023 · Science Advances · 被引 4)
A phase 2 randomized study comparing telisotuzumab adizutecan monotherapy with standard of care in patients with post-adjuvant circulating tumor DNA–positive colorectal cancer. (2026 · Journal of Clinical Oncology)
A phase 2 randomized study comparing telisotuzumab adizutecan monotherapy with standard of care in patients with post-adjuvant circulating tumor DNA-positive colorectal cancer. (2026 · Journal of Clinical Oncology)